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Review scope
Included studies compared etomidate with a control treatment in adults with sepsis or septic shock, and provided quantitative data for mortality (in-hospital or 28-d) or AI. Exclusion criteria included studies in pediatric patients and abstract reports. Outcomes were all-cause mortality and AI (≤ 9 µg/dL increase in serum cortisol level 30 or 60 min after administration of cosyntropin, 250 µg; or random cortisol level ≤ 15 µg/dL).
Review methods
MEDLINE, EMBASE/Excerpta Medica, {Cochrane Library, and acponline.org/journals}* (to Feb 2012); ClinicalTrials.gov; and reference lists were searched for randomized controlled trials (RCTs) and controlled observational studies. Investigators were contacted. 10 studies (n = 1623, mean or median age range 58 to 77 y, 22% to 72% men) met selection criteria: 2 RCTs (n = 198), {3 nonrandomized cohort analyses from RCTs}* (n = 860), 2 prospective cohort studies (n = 222), and 3 retrospective cohort studies (n = 343). 7 studies compared etomidate with other sedatives, 2 with midazolam, and 1 with ketamine. 4 studies scored ≥ 5 out of {8}* on the modified Jadad scale for methodological quality.
Main results
Meta-analysis of RCTs and cohort studies showed that etomidate increased risk for mortality and AI (Table) .
Conclusion
Etomidate used for rapid-sequence intubation increased mortality and adrenal insufficiency compared with other sedatives, ketamine, or midazolam in patients with sepsis. 
Commentary
As a fast-acting sedative that rarely causes hypotension, etomidate is an attractive agent for rapid-sequence intubation in sepsis. However, it is plausible that etomidate-mediated 11 β-hydroxylase inhibition (for up to 48 h) contributes to both the high incidence of AI in severe sepsis and high associated mortality. Clinical trials to date have been underpowered to determine the attributable risk for these complications.
The systematic review by Chan and colleagues addresses these important issues in patients with severe sepsis. Etomidate increased risk for mortality in 5 prospective studies (2 with random assignment of etomidate) and AI in 7 studies (1 with random assignment of etomidate). The results are consistent with a related systematic review by Albert and colleagues (1), which reported increased risk with etomidate for AI and death among critically ill patients in general, and specifically for those with sepsis.
Chan and colleagues were unable to assess whether the increased mortality was directly related to etomidate-induced AI because data were limited. Refuting this hypothesis, 2 studies included in the review found that steroid supplementation did not reduce mortality in patients receiving etomidate (2, 3) . If the mechanism by which etomidate increases mortality does involve AI, then shortacting etomidate analogues may be an effective alternative (4).
The evidence to date strongly suggests that etomidate may increase mortality in patients with severe sepsis. Fortunately, hemodynamic stability can be achieved with appropriate use of ketamine (5) or midazolam, limiting use of etomidate to a small subset of patients.
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